CN103003304B - 结直肠癌和胃肠癌的预防 - Google Patents
结直肠癌和胃肠癌的预防 Download PDFInfo
- Publication number
- CN103003304B CN103003304B CN201180025541.4A CN201180025541A CN103003304B CN 103003304 B CN103003304 B CN 103003304B CN 201180025541 A CN201180025541 A CN 201180025541A CN 103003304 B CN103003304 B CN 103003304B
- Authority
- CN
- China
- Prior art keywords
- seqidno
- antibody
- forms
- aminoacid sequence
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/5758—Gastrin releasing peptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/595—Gastrins; Cholecystokinins [CCK]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (11)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31724510P | 2010-03-24 | 2010-03-24 | |
US61/317,245 | 2010-03-24 | ||
PCT/EP2011/001448 WO2011116954A2 (en) | 2010-03-24 | 2011-03-23 | Prophylaxis of colorectal and gastrointestinal cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103003304A CN103003304A (zh) | 2013-03-27 |
CN103003304B true CN103003304B (zh) | 2016-03-09 |
Family
ID=43989855
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201180025541.4A Expired - Fee Related CN103003304B (zh) | 2010-03-24 | 2011-03-23 | 结直肠癌和胃肠癌的预防 |
Country Status (14)
Country | Link |
---|---|
US (2) | US20150071912A1 (zh) |
EP (1) | EP2550294B1 (zh) |
JP (1) | JP5829672B2 (zh) |
KR (1) | KR101570404B1 (zh) |
CN (1) | CN103003304B (zh) |
AU (1) | AU2011231978B2 (zh) |
BR (1) | BR112012024036B1 (zh) |
CA (1) | CA2793647C (zh) |
EA (1) | EA036967B1 (zh) |
ES (1) | ES2754774T3 (zh) |
NZ (1) | NZ602992A (zh) |
PL (1) | PL2550294T3 (zh) |
SG (1) | SG184092A1 (zh) |
WO (1) | WO2011116954A2 (zh) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2871092T3 (es) * | 2010-07-26 | 2021-10-28 | Progastrine Et Cancers S A R L | Métodos y composiciones para la terapia del cáncer de hígado |
WO2012164035A1 (en) * | 2011-06-01 | 2012-12-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for predicting the risk of developing a colonic neoplasia |
US9271999B2 (en) * | 2012-05-09 | 2016-03-01 | Cantex Pharmaceuticals, Inc. | Treatment of myelosuppression |
CN106659909B (zh) * | 2013-08-21 | 2022-01-11 | 德克萨斯州大学系统董事会 | 用于靶向连接蛋白半通道的组合物和方法 |
US10052346B2 (en) | 2015-02-17 | 2018-08-21 | Cantex Pharmaceuticals, Inc. | Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids |
PL3397964T3 (pl) | 2015-12-31 | 2022-02-07 | Progastrine Et Cancers S.À R.L. | Kompozycje i sposoby do wykrywania i leczenia raka jajnika |
KR102477179B1 (ko) | 2015-12-31 | 2022-12-13 | 프로가스트린 에 캔서스 에스.에이 알.엘. | 위암의 검출 및 치료를 위한 조성물 및 방법 |
EP3397967B1 (en) * | 2015-12-31 | 2020-12-30 | Progastrine et Cancers S.à r.l. | Compositions and methods for detecting and treating esophageal cancer |
CN114705858A (zh) | 2015-12-31 | 2022-07-05 | Syncerus有限责任公司 | 用于评估癌症发生的风险的组合物和方法 |
US11561225B2 (en) | 2017-03-30 | 2023-01-24 | Progastrine Et Cancers S.À R.L. | Compositions and methods for treating lung cancer |
ES2921775T3 (es) | 2017-03-30 | 2022-08-31 | Ecs Progastrin Sa | Composiciones y métodos para detectar y tratar el cáncer de próstata que utilizan la molécula de unión a progastrina |
TWI763956B (zh) * | 2017-12-05 | 2022-05-11 | 盧森堡商前胃泌激素及癌症有限公司 | 治療癌症的抗前胃泌激素抗體與免疫療法之組合療法 |
WO2019110845A1 (en) | 2017-12-08 | 2019-06-13 | Ecs-Biotracker Sàrl | Radiolabeled progastrin in cancer diagnosis |
TW201940881A (zh) | 2018-01-26 | 2019-10-16 | 瑞士商Ecs前胃泌激素公司 | 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術 |
CA3092414A1 (en) | 2018-02-27 | 2019-09-06 | Ecs-Progastrin Sa | Progastrin as a biomarker for immunotherapy |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008076454A1 (en) * | 2006-12-19 | 2008-06-26 | The Board Of Regents Of The University Of Texas System | Immunogenic compositions comprising progastrin and uses thereof |
CN101460196A (zh) * | 2006-05-22 | 2009-06-17 | 国立医学与健康研究所 | 在结肠癌治疗中的前胃泌素抑制剂 |
CN102791735A (zh) * | 2009-10-16 | 2012-11-21 | 拜若提 | 抗前胃泌素的单克隆抗体及其用途 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
AUPO982097A0 (en) * | 1997-10-15 | 1997-11-06 | University Of Melbourne, The | Methods and compositions for use therein |
US20010036635A1 (en) | 2000-03-27 | 2001-11-01 | Waldman Scott A. | Compositions and methods for identifying and targeting cancer cells of alimentary canal origin |
EP1416964A4 (en) | 2001-07-09 | 2005-10-12 | Aphton Corp | TREATMENT AND PREVENTION OF CANCER AND PRECANCEROUS DISEASES OF THE LIVER, LUNG AND ESOPHAGUS |
WO2004090547A2 (en) | 2003-04-04 | 2004-10-21 | Protein Design Labs, Inc. | Metastatic colorectal cancer signatures |
WO2006032980A1 (en) * | 2004-09-22 | 2006-03-30 | Receptor Biologix, Inc. | Monoclonal antibolies to progastrin |
JP2011511071A (ja) | 2008-02-08 | 2011-04-07 | ポニアード ファーマシューティカルズ, インコーポレイテッド | 肺癌を治療するためのピコプラチンおよびアムルビシン |
US20090275546A1 (en) | 2008-04-10 | 2009-11-05 | Istituto Superiore Di Sanita | Diagnostic tests and personalized treatment regimes for cancer stem cells |
EP2337795A2 (en) | 2008-10-01 | 2011-06-29 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
US9217032B2 (en) * | 2010-01-08 | 2015-12-22 | Les Laboratoires Servier | Methods for treating colorectal cancer |
WO2011104338A1 (en) * | 2010-02-26 | 2011-09-01 | Boehringer Ingelheim International Gmbh | Halogen or cyano substituted thieno [2,3-d]pyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions |
-
2011
- 2011-03-23 KR KR1020127027633A patent/KR101570404B1/ko active IP Right Grant
- 2011-03-23 US US14/233,593 patent/US20150071912A1/en not_active Abandoned
- 2011-03-23 AU AU2011231978A patent/AU2011231978B2/en not_active Ceased
- 2011-03-23 WO PCT/EP2011/001448 patent/WO2011116954A2/en active Application Filing
- 2011-03-23 CN CN201180025541.4A patent/CN103003304B/zh not_active Expired - Fee Related
- 2011-03-23 ES ES11710711T patent/ES2754774T3/es active Active
- 2011-03-23 SG SG2012068599A patent/SG184092A1/en unknown
- 2011-03-23 NZ NZ602992A patent/NZ602992A/en not_active IP Right Cessation
- 2011-03-23 JP JP2013500386A patent/JP5829672B2/ja not_active Expired - Fee Related
- 2011-03-23 CA CA2793647A patent/CA2793647C/en not_active Expired - Fee Related
- 2011-03-23 BR BR112012024036-6A patent/BR112012024036B1/pt active IP Right Grant
- 2011-03-23 EA EA201201324A patent/EA036967B1/ru not_active IP Right Cessation
- 2011-03-23 PL PL11710711T patent/PL2550294T3/pl unknown
- 2011-03-23 EP EP11710711.0A patent/EP2550294B1/en active Active
-
2016
- 2016-09-28 US US15/278,246 patent/US10370444B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101460196A (zh) * | 2006-05-22 | 2009-06-17 | 国立医学与健康研究所 | 在结肠癌治疗中的前胃泌素抑制剂 |
WO2008076454A1 (en) * | 2006-12-19 | 2008-06-26 | The Board Of Regents Of The University Of Texas System | Immunogenic compositions comprising progastrin and uses thereof |
CN102791735A (zh) * | 2009-10-16 | 2012-11-21 | 拜若提 | 抗前胃泌素的单克隆抗体及其用途 |
Also Published As
Publication number | Publication date |
---|---|
BR112012024036B1 (pt) | 2020-03-03 |
WO2011116954A8 (en) | 2013-02-21 |
AU2011231978B2 (en) | 2014-12-18 |
KR20130010050A (ko) | 2013-01-24 |
EA201201324A1 (ru) | 2013-08-30 |
AU2011231978A1 (en) | 2012-10-11 |
EA036967B1 (ru) | 2021-01-20 |
US20150071912A1 (en) | 2015-03-12 |
CN103003304A (zh) | 2013-03-27 |
EP2550294A2 (en) | 2013-01-30 |
WO2011116954A3 (en) | 2013-04-25 |
CA2793647A1 (en) | 2011-09-29 |
CA2793647C (en) | 2020-09-01 |
PL2550294T3 (pl) | 2020-03-31 |
NZ602992A (en) | 2014-11-28 |
ES2754774T3 (es) | 2020-04-20 |
BR112012024036A2 (pt) | 2017-07-18 |
WO2011116954A2 (en) | 2011-09-29 |
JP2013527140A (ja) | 2013-06-27 |
US10370444B2 (en) | 2019-08-06 |
KR101570404B1 (ko) | 2015-11-20 |
US20170233469A1 (en) | 2017-08-17 |
JP5829672B2 (ja) | 2015-12-09 |
SG184092A1 (en) | 2012-10-30 |
EP2550294B1 (en) | 2019-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103003304B (zh) | 结直肠癌和胃肠癌的预防 | |
CN103261224B (zh) | 用于肝癌治疗的方法和组合物 | |
CN102791735B (zh) | 抗前胃泌素的单克隆抗体及其用途 | |
CN102933603B (zh) | 用于治疗胰腺癌的方法 | |
AU2017202880B2 (en) | Monoclonal Antibodies to Progastrin and their uses | |
EA041823B1 (ru) | Моноклональные антитела к прогастрину и их применение |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SERVIER LAB Free format text: FORMER OWNER: BIOREALITES Effective date: 20130417 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20130417 Address after: Inside France Applicant after: LES LABORATOIRES SERVIER Applicant after: National Institute of Health and Medicine Applicant after: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) Address before: French Suresnes Applicant before: Byrotti Applicant before: National Institute of Health and Medicine Applicant before: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160309 |